CLINICAL TRIALS PROFILE FOR ZYLOPRIM
✉ Email this page to a colleague
All Clinical Trials for Zyloprim
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00175019 ↗ | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 | Completed | Takeda | Phase 3 | 2003-07-01 | The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout. |
| NCT00241839 ↗ | Uric Acid and Hypertension in African Americans | Completed | University of Florida | Phase 3 | 2005-08-01 | This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans. |
| NCT00430248 ↗ | Efficacy and Safety of Oral Febuxostat in Participants With Gout | Completed | Takeda | Phase 3 | 2007-02-01 | The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout. |
| NCT00602693 ↗ | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | Masonic Cancer Center, University of Minnesota | Phase 1 | 2007-07-23 | RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T-regulatory cells after the transplant may decrease this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. However, the donor immune system may also react against the recipient's tissues (graft-versus-host disease). PURPOSE: This phase I trial is studying the side effects and best dose of donor T-regulatory cells after an umbilical cord blood transplant in treating patients with advanced hematologic cancer or other disorder. |
| NCT00643123 ↗ | Allopurinol Add-on Treatment for Refractory Mania | Completed | National Alliance for Research on Schizophrenia and Depression | Phase 4 | 2007-09-01 | The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania. |
| NCT00643123 ↗ | Allopurinol Add-on Treatment for Refractory Mania | Completed | Cedars-Sinai Medical Center | Phase 4 | 2007-09-01 | The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Zyloprim
Condition Name
Clinical Trial Locations for Zyloprim
Trials by Country
Clinical Trial Progress for Zyloprim
Clinical Trial Phase
Clinical Trial Sponsors for Zyloprim
Sponsor Name
